AZ, Bristol unveil Forxiga in U.K.; Study: Warfarin may be riskier than previously thought;

@FiercePharma: Merck KGaA says it won't offload its consumer health unit, despite promise of big $$. Report | Follow @FiercePharma

> AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) launched their new diabetes drug Forxiga in the U.K. after its European approval earlier this month. Report

> Seattle Genetics ($SGEN) said its cancer treatment Adcetris won orphan drug status for treating mycosis fungoides, the most common type of cutaneous T-cell lymphoma; it's already approved for two other types of lymphoma. Report

> The common blood thinner warfarin is associated with more serious bleeding events in real-world use than in clinical trials, a study found, but the study author cautioned against interpreting the results as an endorsement of newer warfarin alternative drugs. Report

> South Africa's Cipla Medpro said its CFO resigned, soon after CEO Jerome Smith quit amid allegations of financial irregularities. Report

> Despite opposition to vague language in the Massachusetts legislature's provision relaxing the pharma gift ban, the state's Public Health Council implemented it mostly as-is. Report

> Lundbeck hired Ogilvy PR Health to help launch its new antidepressant vortioxetine, which is awaiting approval from European and U.S. regulators. Report

> The British pharma association is once again urging the country's National Health Service to quickly adopt new drugs recommended by the cost-effectiveness watchdog NICE. Report

Biotech News

 @FierceBiotech: In case you missed it: Top 50 Industry Voices in Biotech Twittersphere -- 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: Updated Acadia story with CEO comments on pimavanserin dev plans. Confirm Ph3, pursue schizophrenia and Alzheimer's psychosis. Story | Follow @JohnCFierce

 @RyanMFierce: Why Big Data alone lacks the punch pharma needs. Article | Follow @RyanMFierce

> China fosters biosimilar drug R&D with new set of custom guidelines. More

> Pfizer gets Rhythm with $8M bet on diabetes, obesity drug work. News

Medical Device News

 @FierceMedDev: New special report: Top 10 Diagnostics Companies 2012. Report | Follow @FierceMedDev

@MarkHFierce: Venture funding lives: TriReme Medical pulled in $18 million in a new round. Release | Follow @MarkHFierce

 @DamianFierce: As Mindray Medical knows, being a Chinese company gives you cost advantages but can come with some PR hurdles. More | Follow @DamianFierce

> India's Trivitron expands Dx reach with $20.4M buy. Article

> Merit buys GE unit for $167M. News

Pharma Manufacturing News

> Some 'misbranded drugs' turned up in Avastin probe came from Roche plant. News

> Switzerland, home of Roche and Novartis, gets pass from EU API rule. Story

> EMA wants manufacturers to offer up drug shortage 'risk analysis'. Article

> Novartis gets FDA OK for faster flu vaccine production at U.S. plant. More

Biotech Research News

> German team combines 2 old drugs for new MS treatment. More

> Stem cell-reliant HIV vaccine launches animal studies in January. Article

> Anti-cancer virus could gain new power with patient immune cell tweak. Story

> McGill scientists link autistic behavior to brain protein mutation. Item

And Finally... Short bursts of exercise have an immediate effect on memory in healthy older adults--and in those with mild cognitive problems. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.